STOCK TITAN
  1. Home
  2. News
  3. AVIR

Atea Pharmaceuticals Inc - AVIR STOCK NEWS

IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 in COVID-19
clinical trial covid-19
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
conferences
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Provides Update on Strategic Collaboration with Roche
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2021 Financial Results
earnings
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals to Host Third Quarter Financial Results Conference Call on November 11, 2021
conferences earnings
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting
clinical trial
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals to Present Virology and Early Clinical Data at the ISIRV-WHO Virtual Conference 2021
conferences clinical trial
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals to Present at Guggenheim 2nd Annual Vaccines & Infectious Day Conference
conferences
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
conferences
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752’s Potent In Vitro and In Vivo Activity Against Dengue and Other Flaviviruses
Stock AVIR logo
Atea Pharmaceuticals Inc

Nasdaq:AVIR

AVIR Rankings

#4189 Ranked by Market Cap
#4631 Ranked by Stock Gains
N/A Ranked by Dividends

AVIR Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About AVIR

atea pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. the company's lead product candidate is at-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial. it also develops at-787 which is under phase 2 clinical for the treatment of hepatitis c virus; at-752 which is under phase 2 clinical trial for the treatment of dengue; and at-889, at-934, and other product candidates for the treatment of respiratory syncytial virus are under phase 2 clinical trials. the company was incorporated in 2012 and is based in boston, massachusetts.